The effect of a special formula for patients with diabetic nephropathy requiring enteral nutritional support on nutritional, inflammatory, metabolic, and renal function indicators in critically ill patients admitted to the intensive care unit

The effect of a special formula for patients with diabetic nephropathy requiring enteral nutritional support on nutritional, inflammatory, metabolic, and renal function indicators in critically ill patients admitted to the intensive care unit: a pilot randomized controlled trial.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240605062016N1

Enrollment

Registered

2024-10-13

Start date

2024-12-15

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy. Glomerular disorders in diabetes mellitus

Interventions

Intervention 1: Intervention group: special gavage for diabetic nephropathy patients (a special formula for nephropathy patients with the appropriate percentage of macronutrients and micronutrients fo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients must be willing to participate in the study have an intensivist's diagnosis of diabetic nephropathy be able to receive enteral nutrition within the first 24 to 48 hours of hospitalization not solely rely on parenteral or oral nutrition

Exclusion criteria

Exclusion criteria: Pregnancy failure to initiate nutritional support within the first 24-48 hours contraindications for enteral nutrition

Design outcomes

Primary

Measure	Time frame
Fasting Blood Sugar. Timepoint: At the beginning of the study and on day 7,. Method of measurement: Enzyme colorimetry.;Low density lipoprotein. Timepoint: At the beginning of the study and on day 7,. Method of measurement: Calculation by formula.;A measure of disease severity. Timepoint: Every other day. Method of measurement: SOFA score questionnaire.;Nutritional quality score. Timepoint: At the beginning of the study and on day 7,. Method of measurement: NUTRIC score questionnaire.;High density lipoprotein. Timepoint: At the beginning of the study and on day 7,. Method of measurement: laboratory kit.;Total cholesterol. Timepoint: At the beginning of the study and on day 7,. Method of measurement: laboratory kit.;Triglyceride. Timepoint: At the beginning of the study and on day 7,. Method of measurement: laboratory kit.;Serum albumin. Timepoint: At the beginning of the study and on day 7,. Method of measurement: laboratory kit.;Serum creatinine. Timepoint: At the beginning of the study and on day 7,. Method of measurement: laboratory kit.;Examining the severity of the disease and organ function. Timepoint: At the beginning of the study. Method of measurement: APACHE II questionnaire.;Inflammatory factor hs-crp. Timepoint: At the beginning of the study and day 7. Method of measurement: Kate Eliza.	—

Measure

Time frame

Fasting Blood Sugar. Timepoint: At the beginning of the study and on day 7,. Method of measurement: Enzyme colorimetry.;Low density lipoprotein. Timepoint: At the beginning of the study and on day 7,. Method of measurement: Calculation by formula.;A measure of disease severity. Timepoint: Every other day. Method of measurement: SOFA score questionnaire.;Nutritional quality score. Timepoint: At the beginning of the study and on day 7,. Method of measurement: NUTRIC score questionnaire.;High density lipoprotein. Timepoint: At the beginning of the study and on day 7,. Method of measurement: laboratory kit.;Total cholesterol. Timepoint: At the beginning of the study and on day 7,. Method of measurement: laboratory kit.;Triglyceride. Timepoint: At the beginning of the study and on day 7,. Method of measurement: laboratory kit.;Serum albumin. Timepoint: At the beginning of the study and on day 7,. Method of measurement: laboratory kit.;Serum creatinine. Timepoint: At the beginning of the study and on day 7,. Method of measurement: laboratory kit.;Examining the severity of the disease and organ function. Timepoint: At the beginning of the study. Method of measurement: APACHE II questionnaire.;Inflammatory factor hs-crp. Timepoint: At the beginning of the study and day 7. Method of measurement: Kate Eliza.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohaddeseh Badpey

Tabriz University of Medical Sciences

badpeyma90@yahoo.com+98 938 630 1431

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026